Cervical Cancer
EMPOWER-Cervical 1 (GOG-3016 / ENGOT-cx9): Cemiplimab vs. Chemotherapy in Recurrent/Metastatic Cervical Cancer
RTOG 90-01 (Morris): Pelvic Radiation + Concurrent Cisplatin/5-FU vs Extended-Field Radiation Alone for Locally Advanced Cervical Cancer
GOG 85: Cisplatin/5-FU vs Hydroxyurea with Radiation in Locally Advanced Cervical Cancer
GOG 123: ChemoRT + Adjuvant Hysterectomy for Bulky Stage IB Cervical Cancer
GOG 120: Cisplatin-Based Chemoradiation for Locally Advanced Cervical Cancer
GOG 109: Concurrent Chemoradiation After Radical Hysterectomy for High-Risk Early Cervical Cancer
GOG-278: Nonradical Surgery — QOL and Physical Function in Early-Stage Cervical Cancer
XIA-2025: Camrelizumab + Famitinib vs Camrelizumab vs Chemotherapy in Recurrent/Metastatic Cervical Cancer (Randomized Phase II)
Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.
COMPASSION-16: Cadonilimab for Persistent, Recurrent, or Metastatic Cervical Cancer
Cadonilimab potentially offers better PFS than pembrolizumab and atezolizumab therapies in recurrent advanced metastatic cervical cancer